MENU
CLYM
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Climb Bio (CLYM) Ownership - Who owns Climb Bio?
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
114.88M
P/E Ratio
N/A
Total Cash
98.06M
Projected Growth
N/A
Total Debt
474K
Revenue
N/A
Risk (Beta)
-1.63
Dividend Yield
N/A
Total Cash/Share
1.45
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
CLYM
Capitalization
115M
P/E Ratio
N/A
Risk (Beta)
-1.63
Dividend Yield
N/A
Total Cash
98.1M
Total Cash/Share
1.45
Total Debt
474K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
193M
P/B Ratio
0.59
Cash Flow
N/A
Earnings
-1.78
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
7K
Current Ratio
14.25
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-50.37M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-59.97
Shares Held By Institutions
67.7M
Shares Outstanding - Current
67.6M
Total Liabilities
7.36M
Total Volume MTD
N/A
Value
1
Gain YTD
-5.556
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CLYM showed earnings on May 14, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information